

ASX RELEASE

Volpara expands Board to promote global growth and strategy

- **Volpara appoints company director Mark Bouw as Non-Executive Director**
- **Mark brings 20+ years' consulting and executive leadership experience from health, medical technology, consumer, and pharmaceutical-related industries**
- **Mark provides a unique mix of experiences from his healthcare background as a nurse, his current diverse consulting work, and his past experience building and developing Australasian companies such as Crossmark and Inova**
- **With an MBA from the University of Sydney Business School, executive education at both Stanford University Graduate School of Business and the London School of Economics and Political Science, Mark will support the Company's global commercial growth**

Wellington, NZ, 3 January 2023 Volpara Health Technologies ("Volpara," "the Group," or "the Company"; ASX:VHT), a global leader in software for the early detection of breast cancer, today announced the appointment of Mark Bouw to the Volpara Board of Directors ("Board") as an independent, Non-Executive Director, effective 1 January 2023.

Mark is a highly experienced senior healthcare CEO who brings a wealth of international education and experience in strategy and growth for healthcare and technology companies. As founder and Managing Director of the Mark Bouw Group Pty Ltd., a leading boutique professional services company based in Melbourne, Australia, Mark's clients include global C-suites, capital funds and private equity investors, and entrepreneurs. He is a visiting consultant at Stanford University's Graduate Business School Seed Program in the United States and is a visiting mentor for Stanford's Ignite program.

"Mark's diversity of experiences and management training will bring a unique and welcome perspective to our board as Volpara prepares for its continued growth and upcoming profitability," said Teri Thomas, CEO and Managing Director of Volpara.

Paul Reid, Chair of Volpara, said, "We welcome Mark Bouw to the Board of Volpara and are pleased to attract someone of Mark's background and experience."

Authorisation & Additional Information

This announcement was authorised by the Board of Volpara Health Technologies Limited.

ENDS

For further information, please contact:

Corporate Enquiries

Teri Thomas, CEO

Volpara Health Technologies

teri.thomas@volparahealth.com

t: +64 21 836 870

Media Enquiries

Trevor Chappell

WE Communications

WE-AUVolpara@we-worldwide.com

t: +61 407 933 437

About Volpara Health Technologies Limited (ASX: VHT)

Volpara Health Technologies makes software to save families from cancer. Healthcare providers use Volpara to better understand cancer risk, empower patients in personal care decisions, and guide recommendations about additional imaging, genetic testing, and other interventions. Our AI-powered image analysis enables radiologists to quantify breast tissue with precision and helps technologists produce mammograms with optimal image quality, positioning, compression, and dose. In an industry facing increasing staffing shortages, our software streamlines operations and provides key performance insights that support continuous quality improvement.

Volpara is the preferred partner of leading healthcare institutions around the world. Our software is used in over 2,000 facilities by more than 5,000 technologists, impacting nearly 15 million patients globally. It helps providers conduct more than three million cancer risk assessments each year and can be deployed stand-alone or fully integrated with electronic health record systems, mammography reporting systems, imaging hardware, and genetic laboratories. Volpara holds the most rigorous security certifications and numerous patents and regulatory registrations, including FDA clearance and CE marking. Since listing on the ASX in April 2016, the Company has raised A\$132 million. With an office in Seattle, Volpara is based in Wellington, New Zealand.